image credit: Freepik

AB2 Bio and WuXi Biologics Collaborate on Orphan Drug Manufacture

AB2 Bio, a Swiss clinical-stage biotech company developing therapies for the treatment of severe systemic autoinflammatory diseases, and WuXi Biologics agreed to collaborate to set up and accelerate commercial-scale manufacturing of Tadekinig alfa, AB2 Bio’s recombinant IL-18 binding protein.

AB2 Bio is in the process of transferring manufacturing of Tadekinig alfa for the treatment of primary monogenic emophagocytic Lymphohistiocytosis (HLH) to WuXi Biologics, where commercial scale manufacturing will be conducted. AB2 Bio will prepare the submission of the license application to the FDA and initiate commercialization activities, including scaling-up manufacturing, leveraging WuXi Biologics’ services and capabilities.

Read More on Genetic Engineering and Biotechnology News